GSK Q1 Strength Signals Tariff Resilience
British pharma heavyweight GSK reports a strong start to 2025 with earnings exceeding forecasts and reaffirms its growth outlookâpositioning itself as a stable force even as potential U.S. pharmaceutical tariffs loom.
English 
German